Nfocus Neuromedical Inc reported that it has received CE Mark approval by the European Notified Body, G-Med for its CardioVasc Advantage Vascular Reconstruction Device (VRD) which is intended to treat coronary artery perforations, aneurysms and saphenous vein graft lesions.

The technology of the Advantage VRD is an important demonstration of Nfocus design talent and teamwork, noted company Chairman, Eric P. Milledge. The technical platform behind this device will pave the way for future Nfocus neurovascular products currently in development.

The Advantage VRD is designed for less-invasive endovascular procedures to performed in small vessels.

The Advantage VRD is a significant advance over previous small-vessel stent-grafts, said Martin S. Dieck, President and CEO.

The Advantage VRD has greatly improved flexibility and a smaller crossing profile when compared to competitive devices. The European CE Mark approval gives Nfocus the ability to market this advanced system for the treatment of serious coronary vascular indications. The device is capable of attaining more distal placement with less vessel trauma due to its innovative design.